KRAS. Help on the way?

[GaryG]

Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target [1]. In presenting positive data from a Phase I dose-escalation study of AMG 510, an oral small molecule inhibitor of KRAS G12C. AMG 510 achieved a 50% response rate among non-small cell lung cancer (NSCLC) patients expressing the KRAS G12C mutation.